<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393366</url>
  </required_header>
  <id_info>
    <org_study_id>1030903</org_study_id>
    <nct_id>NCT01393366</nct_id>
  </id_info>
  <brief_title>Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy</brief_title>
  <acronym>FORTIS</acronym>
  <official_title>Facing Obstacles to RDI(Relative Dose Intensity)Through Telephone Intervention Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to conduct a nurse-based telephone intervention study to minimize&#xD;
      toxicity and increase compliance to a combination of Fludarabine-Cyclophosphamide-Rituximab&#xD;
      (FCR) given frontline to Chronic Lymphocytic Leukemia patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of RDI</measure>
    <time_frame>3 years</time_frame>
    <description>Reductions in Relative Dose Intensity, calculated as the difference between initially planned doses of F, C and R and effectively prescribed doses of the 3 drugs, before and after 6 courses of FCR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Toxicity grade III-IV</measure>
    <time_frame>3 years</time_frame>
    <description>rate of grade III-IV toxicities (neutropenia, fever, infections, renal insufficiency), assessment of quality of life and psychological comfort during FCR therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Without AMA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient will be follow only like usual practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With AMA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient will be follow like usual practice, plus 'Telephone Intervention' every week with a nurse to evaluate physical conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telephone Intervention</intervention_name>
    <description>Only for arm AMA, patient will have one phone every week to evaluate physical conditions.</description>
    <arm_group_label>With AMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Practice</intervention_name>
    <description>None, only usual practice.</description>
    <arm_group_label>Without AMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. CLL whatever Binet stage, but with at least one NCIWG2008 criteria indicating a need&#xD;
             for first line treatment.&#xD;
&#xD;
               -  Matutes score must be 4-5/5.&#xD;
&#xD;
               -  Initial cytopenia (due to CLL) are not exclusion criteria.&#xD;
&#xD;
               -  Lymph node biopsy is needed only if suspicion of Richter syndrome.&#xD;
&#xD;
               -  Mandatory pre-therapeutic check-up: FISH in search for deletion del17p and&#xD;
                  del11q, DAT test, haptoglobin levels, creatinine clearance.&#xD;
&#xD;
          2. Eligibility to a treatment with FCR: clearance &gt; 60ml/mn, consider dose adjustments&#xD;
             (recommended by protocol) if clearance30-60ml/mn, and comorbidity score CIRS-G≤11.&#xD;
&#xD;
          3. Signed informed consent&#xD;
&#xD;
          4. Age&gt; or equal 18 years, ECOG PS 0-2.&#xD;
&#xD;
          5. Estimated overall survival&gt;6 months.&#xD;
&#xD;
          6. Conserved liver function (bilirubin&lt;2,5mg/dl, SGPT&lt;4ULN, SGOT&lt;4ULN) except&#xD;
             infiltration due to the disease.&#xD;
&#xD;
          7. Contraception for younger patients.&#xD;
&#xD;
          8. Confident with the use of telephone, no disabling deafness.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Richter syndrome or atypical CLL (Matutes score &lt;4), and/or del17p by FISH&#xD;
&#xD;
          2. Relapse of CLL&#xD;
&#xD;
          3. Contra-indications to fludarabine: auto-immune cytopenia, creatinine clearance&lt;30&#xD;
             ml/mn.&#xD;
&#xD;
          4. Serologies positive for HIV, HBV, or HCV. No active bacterial, viral or fungal&#xD;
             infection&#xD;
&#xD;
          5. Previous history of hypersensibility to any product used in this protocol&#xD;
&#xD;
          6. Denial, or medical or psychological condition preventing completion of the signed&#xD;
             informed consent.&#xD;
&#xD;
          7. Treatment with an investigational agent, or participation to another therapeutic&#xD;
             protocol, 30 days before participating to this study.&#xD;
&#xD;
          8. Pregnant/breastfeeding women.&#xD;
&#xD;
          9. CNS involvement by CLL.&#xD;
&#xD;
         10. Presence of another cancer needing treatment (except basocellular carcinoma or cervix&#xD;
             cancer managed with only surgery or local therapy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loïc YSEBAERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Of Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de la côte basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Ysebaert L, Larcher M, Compaci G, Oberic L, Sahnes L, Banos A, Araujo C, Sommet A, Laurent G, Despas F. Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia. Ann Hematol. 2019 Apr;98(4):931-939. doi: 10.1007/s00277-019-03631-z. Epub 2019 Feb 18.</citation>
    <PMID>30778715</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

